About Opioid-induced Constipation
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.
Technavio's analysts forecast the global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs.
On the basis of the mechanism of action of drugs, the market is grouped into the following categories:
• Peripherally Acting Mu-opioid Receptor Antagonist
• Locally Acting Chloride Channel Activator
• Others
On the basis of the route of administration of drugs, the market is grouped into the following categories:
• Oral
• Parenteral
On the basis of the dosage form of drugs, the market is grouped into the following categories:
• Solid
• Liquid
Technavio's report, Global Opioid-induced Constipation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• Takeda Pharmaceutical
• Valeant Pharmaceuticals International
Other Prominent Vendors
• Abbott
• Bayer
• Boehringer Ingelheim
• C.B. Fleet
• Cosmo Pharmaceuticals
• Daewoong
• Daiichi Sankyo
• GlaxoSmithKline
• Ironwood Pharmaceuticals
• Johnson & Johnson
• Merck
• Mundipharma
• Nektar Therapeutics
• Pfizer
• Progenics Pharmaceuticals
• Shionogi
• SLA Pharma
• Sucampo
• Synergy Pharmaceuticals
• Theravance
Market Driver
• Unmet Medical Needs
• For a full, detailed list, view our report
Market Challenge
• Availability of OTC and Off-label Drugs
• For a full, detailed list, view our report
Market Trend
• Shift to Targeted Therapy
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Amitiza
04.1.2 MovantikMoventig
04.1.3 Relistor
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding Opioid-induced Constipation
07.2 Symptoms
07.3 Pathophysiology
07.4 Epidemiology
07.5 Diagnosis
07.5.1 Patient History
07.5.2 Bristol Stool Form Scale
07.5.3 Physical Examination
07.5.4 Laboratory Tests
07.5.5 Further Investigational Procedures
07.6 Treatment and Management
07.6.1 Pharmacotherapeutic Approach
07.6.2 Non-pharmacotherapeutic Approach
08. Pipeline Portfolio
08.1 Key Information of Pipeline Molecules
08.1.1 Naldemedine
08.1.2 Linaclotide
08.1.3 AxelopranTD-1211
08.1.4 SP-333
08.1.5 Oral Naloxone
09. Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis
10. Market Segmentation by Mechanism of Action
10.1 Peripherally Acting Mu-opioid Receptor Antagonist
10.2 Locally Acting Chloride Channel Activator
10.3 Others
11. Market Segmentation by Route of Administration
11.1 Oral
11.2 Parenteral
12. Market Segmentation by Dosage Form
12.1 Solid
12.2 Liquid
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Takeda Pharmaceutical
21.2.2 Valeant Pharmaceuticals International
21.2.3 AstraZeneca
21.3 Other and Future Prominent Vendors
22. Key Vendor Analysis
22.1 AstraZeneca plc
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Business Segmentation by Revenue 2013
22.1.4 Business Segmentation by Revenue 2011-2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Developments
22.1.8 SWOT Analysis
22.2 Takeda Pharmaceuticals
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation by Revenue 2013
22.2.4 Business Segmentation by Revenue 2013
22.2.5 Geographical Segmentation by Revenue 2013
22.2.6 Business Strategy
22.2.7 Recent Developments
22.2.8 SWOT Analysis
22.3 Valeant Pharmaceuticals International
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation by Revenue 2013
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Business Strategy
22.3.7 Key Developments
22.3.8 SWOT Analysis
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Pipeline Drugs: Opioid-induced Constipation
Exhibit 3: Snapshot of Global Opioid-induced Constipation Market
Exhibit 4: Global Opioid-induced Constipation Market 2014-2019 ($ millions)
Exhibit 5: Segmentation of Global Opioid-induced Constipation Market by Mechanism of Action
Exhibit 6: Segmentation of Global Opioid-induced Constipation Market by Route of Administration
Exhibit 7: Segmentation of Global Opioid-induced Constipation Market by Dosage Form
Exhibit 8: Segmentation of Global Opioid-induced Constipation Market by Geography 2014
Exhibit 9: Drivers of Global Opioid-induced Constipation Market
Exhibit 10: Challenges in the Global Opioid-induced Constipation Market
Exhibit 11: Trends of Global Opioid-induced Constipation Market
Exhibit 12: Takeda Pharmaceuticals: Key Takeaways
Exhibit 13: Valeant Pharmaceuticals International: Key Takeaways
Exhibit 14: AstraZeneca: Key Takeaways
Exhibit 15: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 16: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 17: AstraZeneca plc: Sales by Geography 2013
Exhibit 18: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 19: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
Exhibit 20: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
Exhibit 21: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
Exhibit 22: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 23: Valeant Pharmaceuticals International: Sales by Geography 2013
